Influence of gene P450 (CYP2C9) on clinical efficacy and pharmacokinetics of Piroxicam after third molar surgery
Phase 4
- Conditions
- Stomatognathic diseases. Pathological conditions, signs and symptoms. Other specified disorders of teeth and supporting structuresK08.8
- Registration Number
- RBR-6qgc6m
- Lead Sponsor
- Faculdade de Odontologia de Bauru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Healthy volunteers of both genders; between 18 and 60 years; are not making use of nonsteroidal anti-inflammatory drugs in the last 7 days.
Exclusion Criteria
Local anesthetics allergy, history of gastrointestinal bleeding or ulcers; kidney disease; asthma; allergy or sensitivity to aspirin or any other anti-inflammatory non-steroid agent; pregnant or nursing women; patients using antidepressant; diuretic or aspirin; patients received antibiotics for 30 days prior to surgery.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected outcome:<br>Reduction of consumption of rescue medication associated with piroxicam use in mutated patients for CYP2C9, as assessed by the information contained in the patient's record sheet for the seven-day postoperative period.;Outcome found:<br>Consumption rescue medication associated with the use of piroxicam was the same among patients mutated or not mutated for CYP2C9, evaluated the information contained in the patient's notes sheet as the postoperative period of seven days.
- Secondary Outcome Measures
Name Time Method Expected Outcome:<br>Increased reports of adverse effects in patients mutated during the postoperative period until suture removal seven days after extraction of the included and / or impacted third molar, assessed through the information contained in the patient's chart and records.;Outcome found:<br>Absence of severe adverse effects reports for all patients, mutated or not to CYP2C9 during the postoperative period until suture removal seven days after extraction of third molar included and / or impacted, assessed by the information contained in the medical records and records of the patient.